Citizens Jmp Cuts Kalaris Therapeutics (NASDAQ:KLRS) Price Target to $25.00

Kalaris Therapeutics (NASDAQ:KLRS) had its price objective trimmed by Citizens Jmp from $26.00 to $25.00 in a report published on Wednesday morning,Benzinga reports. The firm currently has a market outperform rating on the stock.

A number of other equities research analysts have also recently weighed in on the company. Morgan Stanley began coverage on Kalaris Therapeutics in a report on Thursday, April 16th. They issued an “overweight” rating and a $14.00 price target on the stock. Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a report on Wednesday. Finally, Wall Street Zen upgraded Kalaris Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $15.60.

Kalaris Therapeutics Price Performance

KLRS opened at $4.90 on Wednesday. The stock has a market cap of $116.57 million, a P/E ratio of -2.28 and a beta of 0.15. The stock’s 50 day simple moving average is $6.50 and its 200 day simple moving average is $7.51. Kalaris Therapeutics has a 1-year low of $2.14 and a 1-year high of $11.88.

Kalaris Therapeutics (NASDAQ:KLRS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06. Research analysts expect that Kalaris Therapeutics will post -2.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Kalaris Therapeutics

Large investors have recently bought and sold shares of the stock. Nano Cap New Millennium Growth Fund L P acquired a new stake in Kalaris Therapeutics during the 4th quarter valued at $34,000. Barclays PLC acquired a new stake in Kalaris Therapeutics during the 4th quarter valued at $51,000. Johnson Financial Group Inc. acquired a new stake in Kalaris Therapeutics during the 3rd quarter valued at $58,000. Keel Point LLC acquired a new stake in Kalaris Therapeutics during the 4th quarter valued at $86,000. Finally, XTX Topco Ltd acquired a new stake in Kalaris Therapeutics during the 4th quarter valued at $92,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.